{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:11:50Z","timestamp":1780920710136,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":91,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K15183"],"award-info":[{"award-number":["23K15183"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101197","type":"journal-article","created":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:22:04Z","timestamp":1775197324000},"page":"101197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rechallenge chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel for patients with non-small cell lung cancer and interstitial lung disease: A multicenter retrospective study"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1668-0704","authenticated-orcid":false,"given":"Taku","family":"Itoh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7875-6399","authenticated-orcid":false,"given":"Go","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukeyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Tamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoichi","family":"Okishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"91 Suppl 2","key":"10.1016\/j.ctarc.2026.101197_bib0001","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6602061","article-title":"The epidemiology of interstitial lung disease and its association with lung cancer","author":"Raghu","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0002","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00408-014-9664-8","article-title":"Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis","volume":"193","author":"Khan","year":"2015","journal-title":"Lung"},{"key":"10.1016\/j.ctarc.2026.101197_bib0003","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.rmed.2014.07.020","article-title":"Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival","volume":"108","author":"Lee","year":"2014","journal-title":"Respir. Med."},{"key":"10.1016\/j.ctarc.2026.101197_bib0004","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"Collard","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ctarc.2026.101197_bib0005","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.lungcan.2010.04.014","article-title":"The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias","volume":"71","author":"Minegishi","year":"2011","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0006","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s10147-019-01516-9","article-title":"Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II study","volume":"24","author":"Fukuizumi","year":"2019","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0007","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.lungcan.2019.09.020","article-title":"A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302)","volume":"138","author":"Asahina","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0008","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1111\/cas.14217","article-title":"Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease","volume":"110","author":"Kenmotsu","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ctarc.2026.101197_bib0009","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/1759-7714.14376","article-title":"A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114)","volume":"13","author":"Sakashita","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00380-2022","article-title":"Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial","volume":"60","author":"Otsubo","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ctarc.2026.101197_bib0011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/oncolo\/oyac226","article-title":"Management of lung cancer in the patient with interstitial lung disease","volume":"28","author":"Frank","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2026.101197_bib0012","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.3390\/cancers16162837","article-title":"Lung cancer and interstitial Lung diseases","volume":"16","author":"Drakopanagiotakis","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ctarc.2026.101197_bib0013","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.clon.2022.02.015","article-title":"Platinum-based chemotherapy \u2018rechallenge\u2019 in advanced non-ovarian solid malignancies","volume":"34","author":"Hack","year":"2022","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0014","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.lungcan.2013.06.022","article-title":"Platinum rechallenge in patients with advanced NSCLC: a pooled analysis","volume":"81","author":"Petrelli","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0015","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1093\/annonc\/mdx419","article-title":"Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy (East Asia S-1 Trial in Lung Cancer)","volume":"28","author":"Nokihara","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0016","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ctarc.2026.101197_bib0017","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0140-6736(03)12190-3","article-title":"Severe acute interstitial pneumonia and gefitinib","volume":"361","author":"Inoue","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101197_bib0018","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ctarc.2026.101197_bib0019","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","article-title":"Predictive factors for interstitial lung disease, antitumor response, and survival in non\u2013small-cell lung cancer patients treated with Gefitinib","volume":"24","author":"Ando","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0020","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cllc.2014.06.003","article-title":"Association between baseline pulmonary status and interstitial lung disease in patients with non-small-cell lung cancer treated with erlotinib\u2013a cohort study","volume":"15","author":"Johkoh","year":"2014","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0021","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.jtho.2020.08.025","article-title":"Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with EGFR T790M-positive NSCLC treated with Osimertinib in Japan","volume":"15","author":"Gemma","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0023","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.lungcan.2019.06.001","article-title":"Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: a multicenter, open-label single-arm phase II trial","volume":"134","author":"Fujimoto","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0024","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jtho.2020.08.018","article-title":"A phase 2 study of Atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis","volume":"15","author":"Ikeda","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0025","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0026","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221108395","article-title":"Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study","volume":"13","author":"Koda","year":"2022","journal-title":"Ther. Adv. Chronic. Dis."},{"key":"10.1016\/j.ctarc.2026.101197_bib0027","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1186\/1471-2407-14-508","article-title":"Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease","volume":"14","author":"Kato","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0028","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00280-015-2775-y","article-title":"Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia","volume":"76","author":"Watanabe","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0029","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00280-014-2670-y","article-title":"Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease","volume":"75","author":"Kenmotsu","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0030","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.resinv.2022.10.009","article-title":"Chemotherapy versus best supportive care in advanced lung cancer and idiopathic interstitial pneumonias: a retrospective multi-centre cohort study","volume":"61","author":"Miyamoto","year":"2023","journal-title":"Respir. Investig."},{"key":"10.1016\/j.ctarc.2026.101197_bib0031","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.lungcan.2018.09.007","article-title":"A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease","volume":"125","author":"Hanibuchi","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0032","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1111\/1759-7714.14645","article-title":"Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease","volume":"13","author":"Otsuka","year":"2022","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0033","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jtho.2023.09.1446","article-title":"Reconsidering the cutoff value for sensitive and refractory relapses in extensive-stage SCLC in the era of immunotherapy","volume":"19","author":"Torasawa","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0034","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1002\/cam4.689","article-title":"A prognostic model for platinum-doublet as second-line chemotherapy in advanced non-small-cell lung cancer patients","volume":"5","author":"Mo","year":"2016","journal-title":"Cancer Med."},{"key":"10.1016\/j.ctarc.2026.101197_bib0035","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1200\/JCO.2012.43.6758","article-title":"Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non\u2013small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial","volume":"30","author":"Ardizzoni","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0036","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.2008.19.1650","article-title":"Randomized phase II and pharmacogenetic study of Pemetrexed compared with Pemetrexed plus carboplatin in pretreated patients with advanced non\u2013small-cell lung cancer","volume":"27","author":"Smit","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0037","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/JTO.0b013e318216ee6b","article-title":"The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer","volume":"6","author":"Kenmotsu","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0038","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2016.03.017","article-title":"Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer","volume":"96","author":"Enomoto","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101197_bib0039","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12016-021-08877-y","article-title":"Hypersensitivity reactions to platinum agents and taxanes","volume":"62","author":"Tsao","year":"2022","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.ctarc.2026.101197_bib0040","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-05-0298","article-title":"Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer","volume":"11","author":"Mielke","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101197_bib0041","article-title":"Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial","volume":"2","author":"Kogure","year":"2021","journal-title":"Lancet Healthy Longev."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:48:41Z","timestamp":1780919321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":41,"alternative-id":["S2468294226001085"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101197","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rechallenge chemotherapy with carboplatin plus paclitaxel or nab-paclitaxel for patients with non-small cell lung cancer and interstitial lung disease: A multicenter retrospective study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101197"}}